Dr. Mitchell’s research interests are in the economic determinants of cancer care delivery. His work has focused on understanding how current reimbursement models in oncology shape physician behavior and care delivery, and in particular how they may create incentives for overuse and overtreatment. He also studies how alternative reimbursement models may achieve better alignment between physician incentives and patient value, in order to improve outcomes and constrain wasteful spending. Additional research interests include drug approval and regulatory policy, drug pricing, and financial toxicity. Dr. Mitchell has a co-appointment with the Genitourinary Oncology Service, and his clinical interests are in the treatment of genitourinary malignancies, particularly prostate, bladder, and kidney cancers.